GHDx
Published on GHDx (https://ghdx.healthdata.org)


Patients with relapsed/refractory chronic lymphocytic leukaemia may benefit from inclusion in clinical trials irrespective of the therapy received: a case-control retrospective analsysis

General Info

Geography 
Global
Coverage type 
Global
Time period covered 
January, 1998 - December, 2000
Data type
Scientific literature
Keywords 
Leukemia

Citation

Authors 
Esteban D, Tovar N, Jiménez R, Santacruz R, Baumann T, Pastor MC, de la Riva A, Carrera E, Chaves S, Royo C, Navarro A, Rodríguez S, Ayuso C, Riu G, Creus N, Gómez B, Giné E, López-Guillermo A, Delgado J
Journal 
Blood Cancer J
Pages 
e356
Publication year 
2015
Suggested citation 
Esteban D, Tovar N, Jiménez R, Santacruz R, Baumann T, Pastor MC, de la Riva A, Carrera E, Chaves S, Royo C, Navarro A, Rodríguez S, Ayuso C, Riu G, Creus N, Gómez B, Giné E, López-Guillermo A, Delgado J. Patients with relapsed/refractory chronic lymphocytic leukaemia may benefit from inclusion in clinical trials irrespective of the therapy received: a case-control retrospective analsysis. Blood Cancer J. 2015; 5: e356.

Source URL:https://ghdx.healthdata.org/record/patients-relapsedrefractory-chronic-lymphocytic-leukaemia-may-benefit-inclusion-clinical